Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Mikhael

Hematology Scottsdale, AZ Medical Doctor

NPI 1972781581 CMS profile 316002

13400 E Shea Blvd, Scottsdale, AZ 85259

Open in the dashboard

General payments

$1,504,411

437 records reported · program years 2019–2025

Research payments

$454,162

Paid to them · 117 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$664,076 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joseph Mikhael of Scottsdale, AZ is reported in the CMS Open Payments database as having received $1,504,411 across 437 general payments and $454,162 in research payments paid to them. Separately, studies naming them as principal investigator received $664,076 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $396,758 43
2025 Research $25,425 12
2024 General $423,200 27
2024 Research $34,668 10
2023 General $66,254 30
2023 Research $104,596 19
2022 General $112,520 66
2022 Research $86,410 13
2021 General $247,012 130
2021 Research $22,753 23
2020 General $141,649 71
2020 Research $113,371 21
2019 General $117,018 70
2019 Research $66,939 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Mikhael
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Joseph Mikhael were reported at $396,758. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Joseph Mikhael Hematology median Middle half National median
2019 $117,018 $1,012 $122–$9,834 $163
2020 $141,649 $1,475 $115–$9,198 $114
2021 $247,012 $1,470 $125–$7,444 $132
2022 $112,520 $1,371 $139–$8,471 $149
2023 $66,254 $1,295 $147–$11,010 $160
2024 $423,200 $1,286 $146–$9,230 $164
2025 $396,758 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $636,275 34 payments
  2. Genzyme Corporation $154,940 75 payments
  3. Amgen Inc. $143,404 48 payments
  4. Sanofi-Aventis U.S. LLC $129,357 36 payments
  5. Karyopharm Therapeutics Inc. $120,192 68 payments
  6. Celgene Corporation $57,803 39 payments
  7. Janssen Research & Development, LLC $55,650 3 payments
  8. Janssen Biotech, Inc. $52,599 37 payments
  9. GlaxoSmithKline, LLC. $39,379 20 payments
  10. E.R. Squibb & Sons, L.L.C. $35,457 17 payments
  11. Other $79,358 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $982,403 132 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $355,954 119 payments
  3. Honoraria $101,821 49 payments
  4. Travel and Lodging $47,779 55 payments
  5. Education $8,274 2 payments
  6. Food and Beverage $5,931 79 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $2,250 1 payment
Products named General payments · program years 2019–2025
  1. ELREXFIO $626,700 27 payments
  2. SARCLISA $187,781 75 payments
  3. XPOVIO $124,113 71 payments
  4. Kyprolis Oncology $85,721 25 payments
  5. DARZALEX $63,519 40 payments
  6. TECVAYLI $58,750 5 payments
  7. Kyprolis Oncology $41,485 20 payments
  8. BLENREP $29,941 13 payments
  9. MOZOBIL $25,761 12 payments
  10. ABECMA $19,430 10 payments
  11. Other $85,667 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $242,015 27 payments
  2. Janssen Research & Development, LLC $87,740 31 payments
  3. Pharmacyclics LLC, An AbbVie Company $54,090 7 payments
  4. Regeneron Pharmaceuticals, Inc. $19,705 8 payments
  5. Genzyme Corporation $18,755 28 payments
  6. BeiGene, Ltd. $13,610 4 payments
  7. BeiGene (Suzhou) Co., Ltd. $6,370 1 payment
  8. F. Hoffmann-La Roche AG $5,745 3 payments
  9. Sanofi-Aventis U.S. LLC $2,719 5 payments
  10. BeOne Medicines Ltd. $2,065 1 payment

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$5,203

Medicare's payments for the services billed

Medicare patients

56

Average age 73

Services billed

104

25 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 50%
Chronic kidney disease 39%
Osteoporosis 30%
Diabetes 23%
Ischemic heart disease 23%
Depression 23%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELREXFIO
  • PFIZER INC. $382,100
$382,100 — —
SARCLISA
  • SANOFI-AVENTIS U.S. LLC $4,985
$4,985 — —
Blincyto
  • Amgen Inc. $4,098
$4,098 — —
XPOVIO
  • Karyopharm Therapeutics Inc. $4,094
$4,094 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

554 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record